A detailed history of Founders Capital Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Founders Capital Management holds 75 shares of VRTX stock, worth $37,683. This represents 0.02% of its overall portfolio holdings.

Number of Shares
75
Previous 75 -0.0%
Holding current value
$37,683
Previous $35,000 2.86%
% of portfolio
0.02%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

BUY
$392.81 - $485.53 $9,820 - $12,138
25 Added 50.0%
75 $35,000
Q1 2024

Apr 10, 2024

BUY
$407.69 - $446.08 $20,384 - $22,304
50 New
50 $20,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Founders Capital Management Portfolio

Follow Founders Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Founders Capital Management with notifications on news.